10594-57-7 Usage
Uses
Used in Scientific Research:
(5alpha,17beta)-17-acetylestran-3-one is used as a research tool for studying the effects of androgens on various physiological processes, such as muscle growth, bone density, and sexual development. Its potent androgen receptor agonist activity allows researchers to explore the intricate mechanisms of androgen action and develop a deeper understanding of their role in the body.
Used in Drug Development:
In the pharmaceutical industry, (5alpha,17beta)-17-acetylestran-3-one is utilized as a lead compound in the development of new drugs targeting androgen receptor-related conditions. Its structural and functional properties make it a promising candidate for the creation of novel therapeutics aimed at treating hormone-related diseases and conditions.
Used in Hormone-Related Condition Treatment:
(5alpha,17beta)-17-acetylestran-3-one may have potential applications in the treatment of hormone-related conditions and diseases. Its androgen receptor agonist activity could be harnessed to develop targeted therapies for conditions where androgen levels or activity are compromised or imbalanced, offering new treatment options for patients in need.
Check Digit Verification of cas no
The CAS Registry Mumber 10594-57-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,5,9 and 4 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 10594-57:
(7*1)+(6*0)+(5*5)+(4*9)+(3*4)+(2*5)+(1*7)=97
97 % 10 = 7
So 10594-57-7 is a valid CAS Registry Number.
10594-57-7Relevant academic research and scientific papers
NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
-
Paragraph 000564, (2020/07/04)
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a,R7b,R11a, R11b, R12a,R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of -C(0)N(R55a)(R55b), -N(R55a)(R55b), -N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
